New pill ZE50-0134 takes on Hard-to-Treat leukemia and lymphoma
NCT ID NCT06708897
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-stage study is testing a new oral drug called ZE50-0134 in 66 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or certain low-grade lymphomas that have come back or not responded to prior treatments. The main goal is to check the drug's safety and find the right dose, while also looking for signs that it can shrink or control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZE50-0134 (oral capsule taken once daily)
- What this could lead to
- If this works, it could point toward a new treatment option for people with blood cancers that have stopped responding to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 66 participants, so it is primarily testing safety. The drug may not work well or could have side effects, and it will take years before it might become available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL (CHRONIC LYMPHOCYTIC LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Norton Cancer Institute, St. Matthews Campus
RECRUITINGLouisville, Kentucky, 40207, United States
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
-
UT Southwestern Medical Center
NOT_YET_RECRUITINGDallas, Texas, 75390, United States
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45221, United States
-
University of North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a new drug combo outsmart resistant lymphomas?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?